-
Product Insights
NewNet Present Value Model: CRISPR Therapeutics AG’s CTX-120
Empower your strategies with our Net Present Value Model: CRISPR Therapeutics AG's CTX-120 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Sandoz Group AG’s Aflibercept Biosimilar
Empower your strategies with our Net Present Value Model: Sandoz Group AG's Aflibercept Biosimilar report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: CRISPR Therapeutics AG’s CTX-131
Empower your strategies with our Net Present Value Model: CRISPR Therapeutics AG's CTX-131 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: CRISPR Therapeutics AG’s CTX-110
Empower your strategies with our Net Present Value Model: CRISPR Therapeutics AG's CTX-110 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Oculis Holding AG’s Dexamethasone Acetate
Empower your strategies with our Net Present Value Model: Oculis Holding AG's Dexamethasone Acetate report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewScailyte AG Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Scailyte AG Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Scailyte AG(Scailyte ) is a Switzerland based developer of artificial intelligence (AI) based software for pharmaceutical discovery, biomedical research and precision diagnostics. Scailyte is headquartered in Sursee, Switzerland. GlobalData's Medical Devices company profile report, “Scailyte AG Pipeline Insight and Competitive Landscape, 2023" provides information about the company overview and analysis on their pipeline products. This company profile report provides key...
-
Product Insights
NewClemedi AG Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Clemedi AG Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Clemedi AG (Clemedi) develops in vitro diagnostic (IVD) tests for antibiotic resistance and susceptibility in infectious diseases. The company is investigating tuberculosis IV test device to identify tuberculosis; IVD tests to detect sexually transmitted infections (STI) causing bacteria; and tests to diagnose hospital acquired infections (HAI) such as ventilator associated pneumonia, urinary tract and surgical infections. It also developed a...
-
Product Insights
NewBayer AG Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Bayer AG Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Bayer AG (Bayer) is engaged in the discovery, development, manufacturing, and commercialization of products for human health, and agriculture. It provides medicines for cardiovascular diseases, women’s health, cancer, hematology, ophthalmology and other indications. It also strives to develop new molecules and technologies for use in the fields of medicine and modern agriculture. The company's product portfolio includes prescription products, specialty...
-
Product Insights
NewGaia AG Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Gaia AG Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Gaia AG is a Germany based digital therapeutics company. The company offers an online treatment programs for patients suffering from unipolar depression. GlobalData's Medical Devices company profile report, “Gaia AG Pipeline Insight and Competitive Landscape, 2023" provides information about the company overview and analysis on their pipeline products. This company profile report provides key information and data related to: Top...
-
Product Insights
NewXeltis AG Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Xeltis AG Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Xeltis AG (Xeltis) is a clinical-stage medical equipment company that harnesses advances in science to improve the treatment of heart valve related conditions. Its polymer-based technology platform, RestoreX, facilitates the natural restoration of heart valve through a process referred to as endogenous tissue restoration (ETR). Based on supramolecular chemistry, the company develops bioabsorbable synthetic heart valves and vascular grafts to...